Chen Huang
Shijiazhuang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Development and Validation of a Novel Geriatric Risk Score for Prognostication in Older Patients With Hodgkin Lymphoma: A Multicenter Retrospective Study.
Journal: American journal of hematology
Published: February 06, 2026
A dual-mechanism model of Selinexor in DLBCL: p53 reactivation and metabolic reprogramming.
Journal: Journal of translational medicine
Published: October 02, 2025
ATF6 and pS6K as prognostic biomarkers in newly diagnosed diffuse large B-cell lymphoma.
Journal: Scientific reports
Published: March 15, 2025
ATF6 activation promotes tumorigenesis and drug resistance in diffuse large B-cell lymphoma (DLBCL) by regulating the mTOR/S6K signaling pathway.
Journal: Discover oncology
Published: January 10, 2025
Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study.
Journal: Hematological oncology
Published: October 08, 2024
Activation of Notch-1 signaling pathway in macrophages to secrete PD-L1 and regulate cytotoxicity of CAR-T cells in diffuse large B-cell lymphoma.
Journal: Aging
Published: May 12, 2023
Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma.
Journal: Frontiers in immunology
Published: July 01, 2022
Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic-sensitizing effects on extranodal NK/T-cell lymphoma cells.
Journal: BMC cancer
Published: May 13, 2022
Genomic Mutation Landscape of Primary Breast Lymphoma: Next-Generation Sequencing Analysis.
Journal: Disease markers
Published: April 18, 2022
Challenges and strategies of clinical application of CAR-T therapy in the treatment of tumors-a narrative review.
Journal: Annals of translational medicine
Published: November 04, 2020
Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study.
Journal: Annals of translational medicine
Published: November 04, 2020
Last Updated: 09/26/2026